Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Accumulated Expenses (2017 - 2025)

Bioceres Crop Solutions' Accumulated Expenses history spans 7 years, with the latest figure at $9.6 million for Q2 2023.

  • For Q2 2023, Accumulated Expenses rose 26.09% year-over-year to $9.6 million; the TTM value through Jun 2023 reached $9.6 million, up 26.09%, while the annual FY2023 figure was $9.6 million, 26.09% up from the prior year.
  • Accumulated Expenses for Q2 2023 was $9.6 million at Bioceres Crop Solutions, up from $7.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $14.9 million in Q4 2021 and bottomed at $4.5 million in Q2 2020.
  • The 5-year median for Accumulated Expenses is $7.6 million (2022), against an average of $8.4 million.
  • The largest annual shift saw Accumulated Expenses dropped 15.8% in 2020 before it grew 26.09% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $5.4 million in 2019, then dropped by 15.8% to $4.5 million in 2020, then surged by 229.25% to $14.9 million in 2021, then crashed by 48.7% to $7.6 million in 2022, then increased by 26.09% to $9.6 million in 2023.
  • Per Business Quant, the three most recent readings for BIOX's Accumulated Expenses are $9.6 million (Q2 2023), $7.6 million (Q2 2022), and $14.9 million (Q4 2021).